MOGN Mgi Pharma (MM)

MGI PHARMA, INC. (Nasdaq:MOGN) today announced that its second quarter 2005 financial results will be webcast live on Wednesday, July 13, 2005 at 5:00 p.m. ET. Lonnie Moulder, president and chief executive officer of MGI PHARMA, and other members of the Company's executive management team will review financial results, provide commentary on MGI PHARMA's business outlook, and answer questions from analysts and investors. All interested parties are welcome to listen to this audio webcast. MGI PHARMA will issue its second quarter 2005 financial results news release after the market closes on Wednesday, July 13, 2005. -0- *T What: MGI PHARMA's Second Quarter 2005 Financial Results Conference Call Webcast When: Wednesday, July 13, 2005 at 5:00 p.m. ET How: Live over the Internet - simply log on to www.mgipharma.com. In addition to the live webcast, the conference will be archived on the Company's Web site for one week. *T About MGI PHARMA MGI PHARMA, INC. is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. MGI PHARMA has a portfolio of proprietary pharmaceuticals, and intends to become a leader in oncology. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Kadian(R) (sustained release morphine sulfate) capsules, Salagen(R) Tablets (pilocarpine hydrochloride) and Hexalen(R) (altretamine) capsules in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets. For more information about MGI PHARMA, please visit www.mgipharma.com. This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," " expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of MGI PHARMA's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the Company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of MGI PHARMA's product candidates to be proven safe and effective in humans, to receive marketing authorization from regulatory authorities, and to ultimately compete successfully with other therapies; continued sales of MGI PHARMA's marketed products; development or acquisition of additional products; reliance on contract manufacturing; changes in strategic alliances; continued access to capital; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q or 10-K. MGI PHARMA undertakes no duty to update any of these forward-looking statements to conform them to actual results.